R
Regard
Uses AI to automatically diagnose patients and generate accurate notes for doctors to improve patient care and reduce burnout
About Regard
Regard is a cutting-edge healthcare technology startup that aims to modernize the practice of medicine by leveraging advanced data analytics and automation. The company primarily serves healthcare providers, including hospitals and clinics, by offering a platform that analyzes and synthesizes patient data. This platform helps in recommending diagnoses, automating note-taking, and capturing missed revenue opportunities. Essentially, Regard's system handles repetitive administrative tasks, allowing healthcare professionals to focus more on patient care.
Operating in the healthcare technology market, Regard addresses a critical need for efficiency and accuracy in medical documentation and diagnosis. The company's business model revolves around a software-as-a-service (SaaS) approach, where healthcare institutions pay for access to its platform. This model ensures a steady revenue stream while providing scalable solutions to its clients.
Regard makes money by charging subscription fees for its platform, which offers significant value by saving clinicians 15-30% of their time and improving hospital finances with an estimated $100K revenue impact per user. By reducing coding queries and enhancing the accuracy of medical records, Regard not only improves operational efficiency but also boosts the financial health of its client institutions.
In summary, Regard is revolutionizing healthcare by automating documentation and enhancing diagnostic accuracy, thereby freeing up valuable time for clinicians and improving hospital revenues.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- New York City, United States
- Employees
- 137
- Open positions
- None listed
- Dealroom signal
- 93.0/100
- Industry
- Health
- Sub-industry
- Health Platform
- Sector
- Health Tech & Medtech, Health Care Information Technology, Core AI, Hard Tech, AI Applications, DT and LS, science-based
- Technology
- Artificial Intelligence, Deep Tech, Machine Learning, Nanotech
- Business model
- SaaS
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jul 2024 | $61M | $244M | Techstars · Cedars-Sinai Health Ventures · TenOneTen Ventures · Calibrate Ventures | ↗ |
| SERIES AOther financing | Jun 2022 | $15M | $61M | Drew Houston · Brook Byers · Foundry · Calibrate Ventures | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Regard is 11K monthly website visits, up 29.4% over the last three months. Regard's team grew 19.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Susa Ventures
Calibrate Ventures
TenOneTen Ventures
Series A7 investors entered at this stage
Right Side Capital Management
Foundry
Drew Houston
Brook Byers
Oak HC/FT
Techstars- CVCedars-Sinai Health Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Regard on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Regard’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







